Harrow (NASDAQ:HROW) Price Target Increased to $30.00 by Analysts at Craig Hallum

Harrow (NASDAQ:HROW) had its target price boosted by Craig Hallum from $26.00 to $30.00 in a research note issued to investors on Friday, Benzinga reports. Craig Hallum currently has a buy rating on the stock.

HROW has been the subject of a number of other reports. B. Riley reissued a buy rating and set a $29.00 price target (up from $26.00) on shares of Harrow in a research note on Wednesday, May 15th. Lake Street Capital increased their price target on Harrow from $20.00 to $25.00 and gave the company a buy rating in a research note on Monday, June 3rd.

Harrow Stock Performance

NASDAQ:HROW opened at $21.00 on Friday. The company has a current ratio of 3.00, a quick ratio of 2.75 and a debt-to-equity ratio of 3.06. Harrow has a 12-month low of $7.60 and a 12-month high of $22.63. The stock has a 50-day moving average price of $14.82 and a 200 day moving average price of $12.22. The stock has a market capitalization of $742.98 million, a P/E ratio of -23.08 and a beta of 0.88.

Harrow (NASDAQ:HROW) last released its earnings results on Monday, May 13th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.25) by ($0.03). Harrow had a negative return on equity of 39.82% and a negative net margin of 22.59%. The business had revenue of $34.59 million for the quarter, compared to analysts’ expectations of $34.37 million. Equities research analysts forecast that Harrow will post -0.51 EPS for the current fiscal year.

Insider Activity

In related news, major shareholder Opaleye Management Inc. acquired 50,000 shares of the stock in a transaction dated Thursday, March 28th. The stock was acquired at an average cost of $12.82 per share, with a total value of $641,000.00. Following the purchase, the insider now directly owns 3,745,600 shares of the company’s stock, valued at $48,018,592. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders purchased 111,115 shares of company stock valued at $1,271,411 in the last ninety days. Insiders own 13.67% of the company’s stock.

Institutional Investors Weigh In On Harrow

Institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. lifted its stake in shares of Harrow by 347.5% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 4,063 shares of the company’s stock valued at $46,000 after purchasing an additional 3,155 shares during the last quarter. Tower Research Capital LLC TRC lifted its stake in shares of Harrow by 122.2% during the 4th quarter. Tower Research Capital LLC TRC now owns 8,073 shares of the company’s stock worth $90,000 after acquiring an additional 4,440 shares during the last quarter. Bayesian Capital Management LP bought a new stake in shares of Harrow during the 1st quarter worth approximately $185,000. Price T Rowe Associates Inc. MD lifted its stake in shares of Harrow by 6.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,672 shares of the company’s stock worth $221,000 after acquiring an additional 1,033 shares during the last quarter. Finally, BNP Paribas Financial Markets lifted its stake in shares of Harrow by 12.7% during the 1st quarter. BNP Paribas Financial Markets now owns 16,941 shares of the company’s stock worth $224,000 after acquiring an additional 1,912 shares during the last quarter. 72.76% of the stock is owned by institutional investors.

About Harrow

Harrow Health, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company also holds equity interests in Surface Ophthalmics, Inc, a clinical-stage pharmaceutical company that focuses on the development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc, a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc, a commercial-stage pharmaceutical company that engages in developing and commercializing drug products.